US FDA clears Jubilant Therapeutics’ IND for novel dual LSD1 & HDAC6 inhibitor, JBI-802 for treatment of solid tumours

by admin
0 comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy
WP2Social Auto Publish Powered By :